Navigation Links
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Date:11/20/2012

CAMBRIDGE, Mass., Nov. 20, 2012 /PRNewswire/ -- Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat genetically defined cancers, today announced the publication of a contemporary review on targeting protein methyltransferases for personalized cancer therapeutics in the Nature Publishing Group journal Oncogene.

"This publication provides a comprehensive review of the histone methyltransferase (HMT) target class, the genetic alterations in these enzymes that drive specific human cancers and the ongoing efforts to identify and develop potent, selective inhibitors of these enzymes as the basis for novel, personalized cancer therapeutics," said Robert Copeland, Ph.D., Executive Vice President and Chief Scientific Officer of Epizyme. "The review highlights the significant progress that has been made in this field over the past five years and provides a clear foundation for the clinical development of HMT inhibitors (HMTi) that is now underway."

Epizyme has identified 96 histone methyltransferases and determined that 20 play an important role in cancer; these are prime targets for drug development. The company's programs to develop inhibitors for DOT1L for MLL-rearranged leukemia and EZH2 for mutant-bearing Non-Hodgkin lymphoma are examples of Epizyme's approach to creating personalized therapeutics for these genetically defined cancers.

The paper titled, "Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics," was authored by Robert A. Copeland, Mikel P. Moyer and Victoria M. Richon at Epizyme, and is available online.

About Epizyme

Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a class of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.

Epizyme has benchmark alliances with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). For more information, visit www.epizyme.com.

Media Contact
Megan Lustig
Spectrum
202.955.6222 ext. 2586
mlustig@spectrumscience.com


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
2. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
3. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
4. Pharmspective Publishes New Assessment of Impact of State Exchanges on Key Insurers and Pharma
5. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
6. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
7. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
8. Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents
9. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
10. Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
11. Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016   ... the importance of extending care beyond the implant at ... Sessions, May 4-7 in San Francisco ... with continually delivering the highest quality of patient care ... patients are cared for each and every tomorrow," said ...
(Date:5/3/2016)... , May 3, 2016 ... pay $55 million to a woman who says its ... court awarded Gloria Ristesund $5 million in ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... accusations against the company. In February, the same court ...
(Date:5/3/2016)... TUSTIN, Calif. , May 3, 2016 /PRNewswire/ ... science teaching tool that shows how a cleanroom ... for classroom discussions about science and technology. ... Manager said, "As a technology company, SSF enthusiastically ... program to help educators foster the next generation ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been named ... by the American Institute of Architects and the Academy of Architecture for Health. The ... and Harrell Architects, opened to patients in October of 2014. , ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
(Date:5/5/2016)... ... May 05, 2016 , ... In order to increase ... patterns, Amerec, a Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ ... interface of the app, developed for both smartphones and personal computers perfectly emulates ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... on the eve of National Nurses Week (May 6-12). Currently, HireNurses is ... With their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically ...
(Date:5/5/2016)... ... , ... Chronic stress can have a silent, yet dangerous, impact on men’s ... and increase inflammation, both of which raise the risk of heart attack and even ... at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other issues that ...
Breaking Medicine News(10 mins):